ArticleNeuro-oncology advances
Rethinking treatment de-escalation in elderly glioblastoma: Lessons from a multicenter real-world cohort.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) in elderly patients (≥65 years) carries a poor prognosis and higher treatment toxicity. Consequently, many receive de-escalated regimens, often guided by MGMT promoter methylation. However, real-world outcomes across treatment strategies remain underreported and often lack molecular and functional detail. Methods: We retrospectively analyzed 573 elderly GBM patients treated between 2009 and 2023 at 2 Israeli tertiary centers. Post-operative treatments included (1) chemoradiotherapy (CRT; 60Gy in 30 fractions or 40Gy in a15 fractions), (2) temozolomide (TMZ) monotherapy, (3) radiotherapy alone (RT), or (4) best supportive care. MGMT status and Karnofsky Performance Status (KPS) were analyzed where available. Survival was assessed using Kaplan-Meier and log-rank tests. Results: Median overall survival (mOS) was longest with CRT (14 months), compared to 8 months for TMZ and RT monotherapies and 2 months for best supportive care. Among MGMT-methylated patients, CRT yielded mOS of 23 months versus 8 months for TMZ alone. Younger age, surgical resection, and higher KPS predicted longer survival. In the TMZ subgroup, toxicity was low (6% hematologic, 12% non-hematologic grade 3-4 events) and survival improved with increasing TMZ cycles. Salvage therapy after progression was also associated with longer survival. Limitations include retrospective design, incomplete molecular data, frailty and QOL data not collected routinely, potential selection bias, and evolving treatment practices. Conclusion: Fit elderly patients with GBM may achieve benefit from full standard-of-care therapy. Treatment decisions should be guided by functional and clinical fitness rather than chronological age. These real-world data highlight the importance of integrating clinical and functional factors into management of elderly GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.